Overall verdict
Neutral
5.5/10
1-year performance
+87.03%
Score breakdown
Up 87.0% over 1 year, 55% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
6 analysts, target +0.9% vs the price.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications ;
SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema ; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies ;
and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Craig Parker
Founded
2015
Employees
44
Revenue / employee
79 023 USD
Next earnings
November 6, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
37.83 USD
52-week low
11.39 USD
1-year performance
87.03%
Rising
Year-to-date performance
12.22%
Rising
Drawdown
-31.77%
Major drawdown
Position in the 52-week range
55% of range
Gross margin 98.1%, the company loses 3042.9% of its revenue, ROIC 18.4%, ROE 387.2%.
Net margin
-3042.91%
Negative
Sector -223.73%|S&P 13.15%
Gross margin
98.08%
Exceptional
Return on equity (ROE)
387.21%
Exceptional
Sector -58.80%|S&P 16.61%
Return on invested capital (ROIC)
18.36%
Fair
Free cash flow margin (FCF)
-303.92%
Negative
Revenue to net income
Growth
6.7/10Revenue up 408.6% over 1 year.
Revenue (trailing 12 months)
11.5M USD
Revenue growth (1y)
408.65%
Hyper-growth
Revenue growth (3y)
-72.18%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
303M USD
Financial strength
10.0/10Cash covers 1615.6% of the debt.
Net debt / EBITDA
—
Gearing (net debt / equity)
—
Cash
102M USD
Cash / market cap
33.64%
Very solid
Cash / total debt
1615.56%
Net cash
Net debt
-95.7M USD
Equity
-219M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 25.32 USD
- MM2027.46
- MM5023.71
- MM20024.79
- RSI 1451.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.19%
200-day average slope, 3 months
+9.61%
50-day average slope, 1 month
+9.89%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
24.81 % per day
Volatility change
+234.25%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -7.01 (6) | -9.14 (1) | 11 (5) | — | -118 (5) |
| 2027 | -3.61 (6) | -4.19 (3) | 2 (5) | — | -79 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 13, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 303M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | 18.4 % | — | -11.5 % | 87.0 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.7 | 3.0 | 279M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.0 % | -46.6 % |
